KSKashvi Sethuraman

Kashvi Sethuraman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kashvi Sethuraman has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Indoxyl Sulfate Promotes Uremic Arterial and Venous Thrombosis by Stabilizing Indoleamine 2,3-Dioxygenase 1 via the E3 Ligase Split-Hand/Foot Malformation 3

    by Ricardo Almiron, Abbas Brahim Malloum, Saran Lotfollahzadeh, Kashvi Sethuraman, Arjun Sharma, Isaac Selinger, Anna Natrakul, Arjun Patel, David Jasen Wu Wong, Farihah Chowdhury, et al.

    Key Points: Indoleamine 2,3-dioxygenase 1 is a central regulator of tryptophan metabolism and contributed to CKD-associated thromboinflammation and endothelial dysfunction. Indoxyl sulfate, a protein-bound uremic toxin, stabilized indoleamine 2,3-dioxygenase 1 by partially inhibiting its interaction with split-hand/foot malformation 3 and reducing ubiquitination. Targeting indoleamine 2,3-dioxygenase 1 degradation by modulating split-hand/foot malformation 3 may offer a novel therapeutic approach to mitigate CKD-associated arterial and venous thrombosis. Background: The uremic milieu of CKD is characterized by the accumulation of protein-bound uremic toxins, which contribute to thrombosis. Indoxyl sulfate, a bona fide uremic toxin, upregulates indoleamine 2,3-dioxygenase 1 (IDO1), thereby augmenting kynurenine biogenesis. Both toxins activate tissue factor and thrombosis. Despite this pathogenic synergy, the mechanisms of indoxyl sulfate–mediated IDO1 stabilization remain undefined. Methods: We employed targeted metabolomics, super-resolution microscopy, and gain- and loss-of-function experiments using nanoparticle-mediated gene delivery in mice to modulate split-hand/foot malformation 3 (SHFM3) expression. This was followed by carotid artery or inferior vena cava thrombosis assays in indoxyl sulfate–fed and adenine-induced CKD models. Results: Among several F-box–containing E3 ligases, SHFM3 downregulated IDO1 in endothelial cells. SHFM3 constitutively interacted with IDO1, which is partially disrupted by indoxyl sulfate–induced nuclear sequestration of SHFM3 at concentrations corresponding to early-to-advanced CKD. SHFM3 interacted with the N-terminus of IDO1, ubiquitinated, and destabilized it. Indoxyl sulfate upregulated IDO1 activity, thereby increasing kynurenine biogenesis in N-terminus– and SHFM3-dependent manners. In an indoxyl sulfate–fed mouse model, endothelial cell–specific SHFM3 knockdown increased IDO1 and tissue factor while accelerating arterial thrombosis, and these effects were reversed by endothelial cell–specific SHFM3 overexpression. CKD mice exhibited 55% higher venous thrombogenicity than controls. Endothelial cell–specific SHFM3 overexpression significantly reversed these effects in control mice and, to a lesser extent, in CKD mice. Serum indoxyl sulfate levels significantly correlated with the global IDO1 activity and venous clot weights. Conclusions: SHFM3 functions as an indoxyl sulfate–sensitive potent E3 ligase of IDO1, targeting it for degradation, even with partial interaction with IDO1 in the uremic milieu. This work also described a CKD-induced venous thrombosis model and supports the selective rewiring of uremic toxins in post-translational proteostasis, amplifying indoxyl sulfate–mediated arterial and venous thrombosis.